Tarsus Pharmaceuticals, Inc. Stock Price, News & Analysis

Tarsus Pharmaceuticals (NASDAQ: TARS) has appointed Jeff Farrow as Chief Financial Officer and Chief Strategy Officer, effective immediately. Farrow succeeds Leo Greenstein, who left to pursue other interests. Jeff brings over 20 years of experience in finance and corporate strategy within the life sciences sector, notably serving as CFO at Global Blood Therapeutics and holding similar roles at ZS Pharma and Hyperion Therapeutics. CEO Bobak Azamian expressed confidence in Farrow's leadership to drive Tarsus' transition into a commercial organization, particularly in developing therapies for eye care. Tarsus is advancing its lead candidate, TP-03, for treating Demodex blepharitis, which could potentially benefit millions of patients. The New Drug Application for TP-03 has been submitted to the FDA, with a target decision date of August 25, 2023. Tarsus is focused on addressing unmet needs in eye care and other therapeutic areas.

Tarsus Pharmaceuticals reports progress in eye care treatments, with a focus on Demodex blepharitis. The NDA for TP-03 was accepted, targeting FDA action by August 25, 2023. Market research showed over 90% of optometrists would prescribe TP-03 if approved. Completion of the Ersa Phase 2a trial for Meibomian Gland Disease is expected to yield topline data in H2 2023. Cash runway is projected into H2 2026, supporting ongoing development, including TP-04 for rosacea, which has shown positive Phase 1 results. However, the company reported a net loss of $62.1 million for 2022, a notable increase from $13.8 million in 2021.